Hereditary Hemochromatosis as a Risk Factor for Joint Replacement Surgery - 19/08/11
, Tomáš Dallos, MD a, c, , Elmar Aigner, MD b, , Roland Axmann, MD a, Matthias Engelbrecht a, Maximilian Schöniger-Hekele, MD d, Thomas Karonitsch, MD e, Martin Farkas, MD f, Thomas Karger, MD g, Johann Willeit, MD h, Ulrich Stölzel, MD i, Gernot Keyßer, MD j, Christian Datz, MD b, Stefan Kiechl, MD h, Georg Schett, MD a, Jochen Zwerina, MD a, ⁎ 
Reprint requests should be addressed to Jochen Zwerina, MD, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Krankenhausstrasse 12, 91054 ErlangenAbstract |
Objective |
Hemochromatosis is an inherited disease with iron overload and joint involvement resembling osteoarthritis. To determine the rate of joint replacement surgery in patients with hemochromatosis, we performed a cross-sectional cohort study.
Methods |
A total of 199 individuals with hereditary hemochromatosis were included. The prevalence of joint replacement surgery in hip, knee, and ankle joints because of secondary osteoarthritis was assessed. Data were compared with 917 healthy subjects from the population-based Bruneck study.
Results |
A total of 32 of 199 individuals with hemochromatosis received joint replacement surgery with a total number of 52 joints replaced. Compared with expected rates in healthy individuals, patients with hemochromatosis had a significantly higher risk for joint replacement surgery (odds ratio 9.0; confidence interval, 4.6-17.4). Joint replacement occurred significantly earlier in life in patients with hemochromatosis; 21.9% of the patients with hemochromatosis and 1.7% of healthy individuals required joint replacement before the age of 50 years (P=.0027). Moreover, patients with hemochromatosis were more likely to require multiple joint replacements (8.5%) than the control group (expected rate 0.3%; P=.0001).
Conclusion |
Hemochromatosis is a risk factor for joint replacement surgery because of severe secondary osteoarthritis.
Le texte complet de cet article est disponible en PDF.Keywords : Arthritis, Hemochromatosis, Osteoarthritis, Total joint replacement
Plan
| Funding: This study is funded by grants from the German Society of Rheumatology (JZ and GS), Articulum Fellowship (TD), ANCYLOSS project of the Bundes-ministerium für Bildung und Forschung (BMBF; to GS), Spondyloarthritis Immunology Research Alliance (SpIRAL), Masterswitch, Kinacept, and Adipoa projects of the European Union (all GS), and Interdisciplinary Centre for Clinical Research at the University of Erlangen (JZ and GS). |
|
| Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
Vol 123 - N° 7
P. 659-662 - juillet 2010 Retour au numéro
Article précédent
- The Reply
- David U. Himmelstein, Steffie Woolhandler
- A Systems Approach to Morbidity and Mortality Conference
- Jason H. Szostek, Mark L. Wieland, Laura L. Loertscher, Darlene R. Nelson, Christopher M. Wittich, Furman S. McDonald, Joseph C. Kolars, Darcy A. Reed
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?